In a comparison of two different diet and two different weight management programs, results of the international PREVIEW intervention study found a low, similar rate of progression to type 2...

Results from several studies of Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight...

Brad Keywell, CEO of US-based Uptake Technologies, Inc., was this evening named EY World Entrepreneur Of The Year™ 2019 at an award ceremony held in Monaco's Salle des Etoiles. Brad was selected...

By continuing to follow the cohort from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study sponsored by the National Institutes of Health (NIH), researchers can now...

The iLet bionic pancreas (BP)1 significantly increased the percentage of time adults with type 1 diabetes (T1D) had glucose levels between 70–180 mg/dl, when compared to usual care (UC) therapy...